Pharma C Investments - Issue of Equity
Announcement provided byPharma C Investments Plc · PCIL
30 June 2022
Pharma C Investments Plc
("Pharma C" or the "Company")
Issue of Equity
Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry, is pleased to announce that is has raised
Application will be made for them to be admitted to trading on AQSE, which is expected to be on or around 8 July 2022.
The new ordinary shares will rank pari passu with the existing ordinary shares of the Company. Following the issue of the new ordinary shares, the Company's issued share capital will comprise 349,857,144 ordinary shares of 0.1p (including the 80 million new ordinary shares).
The above figure of 349,857,144 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Directors of Pharma C Investments plc take responsibility for this announcement.
This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).
- Ends -
Gavin Sathianathan, Investment Strategy Director, Pharma C Investments
David Coffman / Lucy Bowden
(AQSE Corporate Adviser)
Tel: +44 207 399 9429
About Pharma C
Pharma C Investments is an investment vehicle targeting the legal medicinal cannabis industry globally. The Company is seeking to identify breakout companies within the legal markets with a particular focus on the